5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy

Cardiovascular medications—specifically beta-adrenergic receptor antagonists (beta-blockers) and calcium channel blockers (CCBs)—are among the most lethal prescription ingestions encountered in clinical toxicology. According to national poison center surveillance data, calcium channel blockers and beta-blockers consistently account for the highest proportion of prescription drug-related cardiovascular fatalities. In acute overdose, therapeutic selectivity is rapidly lost, transforming targeted antihypertensive or rate-controlling agents into life-threatening suppressors of myocardial excitation-contraction coupling, electrical conduction, and metabolic fuel delivery.

---

Beta-Adrenergic Antagonists: Pathophysiology and Agent-Specific Features

Beta-blockers competitively inhibit beta-1, beta-2, and beta-3 adrenergic receptors. Under physiological conditions, beta-1 activation stimulates adenylyl cyclase via the stimulatory G-protein (Gs), converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP activates protein kinase A (PKA), which phosphorylates L-type calcium channels and the sarcoplasmic reticulum regulatory protein phospholamban, augmenting intracellular calcium flux and cardiac inotropy, chronotropy, and dromotropy. In overdose, receptor saturation prevents catecholamines (epinephrine, norepinephrine) from binding, depleting intracellular cAMP and precipitating severe bradycardia, atrioventricular (AV) nodal blockade, and myocardial depression.

However, the clinical spectrum of beta-blocker poisoning varies substantially depending on distinct pharmacological properties: lipophilicity, membrane-stabilizing activity (fast sodium channel blockade), intrinsic sympathomimetic activity, and potassium channel blockade.

Propranolol: The Prototype Lipophilic Cardiotoxin

Propranolol is uniquely lethal among beta-blockers due to two distinct properties:

1. High Lipophilicity and Central Nervous System (CNS) Toxicity: Propranolol rapidly traverses the blood-brain barrier. Patients frequently present with sudden coma, central hypoventilation, and generalized tonic-clonic seizures within 30 to 90 minutes of ingestion, often preceding hemodynamic collapse.
2. Membrane-Stabilizing Activity (MSA): Propranolol directly blocks cardiac fast inward sodium channels (Nav1.5) in Phase 0 of the cardiac action potential, identical to Class IA/IC antiarrhythmics and tricyclic antidepressants. This manifests on the 12-lead ECG as progressive QRS widening (>100 ms), right bundle branch block morphology, terminal rightward axis deviation, and monomorphic ventricular tachycardia. Hypertonic sodium bicarbonate (1-2 mEq/kg IV bolus) is indicated to displace the drug from myocardial sodium channels.

Sotalol: The Repolarization Hazard

Sotalol is a non-selective beta-blocker that possesses potent Class III antiarrhythmic properties. It competitively inhibits the rapid component of the delayed rectifier outward potassium current (IKr encoded by KCNH2 / HERG). In overdose, inhibition of outward potassium repolarization dramatically prolongs Phase 3 of the ventricular action potential, producing marked QT and QTc interval prolongation. This creates electrical instability and triggered early afterdepolarizations (EADs), predisposing to Torsades de Pointes (TdP), polymorphic ventricular tachycardia, and ventricular fibrillation. Cardiotoxicity may be delayed up to 24 to 48 hours post-ingestion. Management of sotalol-induced TdP requires intravenous magnesium sulfate (2 g IV), overdrive pacing (target heart rate 100-110 bpm), or cautious isoproterenol infusion, while avoiding Class IA, IC, and III antiarrhythmics.

---

Calcium Channel Blockers: Dihydropyridines vs. Non-Dihydropyridines

Calcium channel blockers inhibit voltage-gated L-type calcium channels (Cav1.2) in vascular smooth muscle, cardiac myocytes, and nodal conduction tissue. Under physiological conditions, calcium influx through L-type channels triggers calcium-induced calcium release from the sarcoplasmic reticulum (via ryanodine receptors), providing the free cytosolic calcium required for actin-myosin cross-bridge cycling and muscular contraction. In vascular smooth muscle, calcium influx maintains arteriolar tone.

Dihydropyridines vs. Non-Dihydropyridines in Overdose

• Non-Dihydropyridines (Verapamil, Diltiazem): These agents exhibit high affinity for cardiac nodal and myocardial L-type calcium channels. Toxicity results in profound negative inotropy (pump failure), negative chronotropy (sinus bradycardia, sinus arrest), and negative dromotropy (first-degree, second-degree, or complete third-degree AV block with slow junctional escape rhythms). Verapamil and diltiazem are the most dangerous calcium channel blockers in overdose; a modest multiple of the daily dose of an extended-release formulation can cause cardiogenic shock in adults, and a single tablet can endanger a toddler.
• Dihydropyridines (Amlodipine, Nifedipine, Nicardipine): At therapeutic doses, these agents selectively bind L-type channels on vascular smooth muscle, causing peripheral arteriolar vasodilation. In mild-to-moderate overdose, they present with hypotension accompanied by reflex sinus tachycardia. However, in massive overdose, vascular selectivity is completely lost. Dihydropyridines saturate myocardial and nodal calcium channels, producing direct myocardial depression, conduction delay, and refractory vasoplegic shock indistinguishable from verapamil toxicity.

Pancreatic Beta-Cell Inhibition: The Hyperglycemia Hallmark

An essential toxicological mechanism distinguishing calcium channel blocker overdose from beta-blocker overdose is the effect on pancreatic endocrinology. Normal pancreatic beta-cell insulin secretion is an active, calcium-dependent process: glucose enters beta cells via GLUT2 transporters, generating ATP, which closes ATP-sensitive potassium (K_ATP) channels; the resulting membrane depolarization opens voltage-gated L-type calcium channels, triggering calcium influx and insulin exocytosis.

Glucose Entry (GLUT2) → ATP Generation → K_ATP Channel Closure → Membrane Depolarization
                                                                          ↓
      L-Type Ca2+ Channel Inhibition (CCB Toxicity) ← [L-Type Ca2+ Channels Open]
                     ↓                                                    ↓
         Failure of Insulin Exocytosis                             Ca2+ Influx
                     ↓                                                    ↓
Profound Hypoinsulinemia & Hyperglycemia (>250-400 mg/dL)    Normal Insulin Exocytosis

In acute CCB toxicity, blockade of beta-cell L-type calcium channels halts insulin release. Combined with stress-induced catecholamine release and peripheral insulin resistance from shock, serum glucose concentrations surge dramatically. Marked hyperglycemia (>200-400 mg/dL) is a hallmark of severe calcium channel blocker toxicity and directly correlates with hemodynamic instability and in-hospital mortality. Conversely, in isolated beta-blocker overdose, blood glucose is typically normal or mildly hypoglycemic (due to inhibition of beta-2-mediated glycogenolysis and gluconeogenesis).

---

High-Dose Insulin Euglycemia (HIE / HDIE) Protocol

High-Dose Insulin Euglycemia (HIE) has superseded traditional vasopressors and high-dose glucagon as the definitive first-line inotropic therapy for moderate-to-severe calcium channel blocker and beta-blocker poisoning.

Physiological and Metabolic Rationale

Under normal resting aerobic conditions, the adult myocardium derives 60% to 90% of its energy from free fatty acid (FFA) oxidation, with glucose contributing only 10% to 40%. In severe shock and myocardial ischemia, fatty acid oxidation becomes inefficient and requires excessive oxygen. The stressed myocardium shifts toward carbohydrate metabolism, which produces significantly more ATP per mole of oxygen consumed.

However, in CCB and BB toxicity, two barriers prevent this vital metabolic shift:

1. Calcium channel blockers inhibit pancreatic insulin secretion, creating absolute hypoinsulinemia.
2. Circulating stress hormones (cortisol, epinephrine) and tissue hypoperfusion induce profound peripheral and myocardial insulin resistance, preventing glucose transport into myocytes.

Exogenous high-dose regular human insulin overcomes this resistance by activating myocyte insulin receptors, translocating GLUT4 glucose transporters to the sarcolemmal membrane, and driving glucose uptake. Inside the myocyte, insulin enhances pyruvate dehydrogenase activity, augmenting aerobic glycolysis and ATP generation. Crucially, insulin directly improves calcium handling by stimulating the sarcoplasmic reticulum calcium-ATPase (SERCA2a) pump, increasing calcium uptake into the sarcoplasmic reticulum and restoring excitation-contraction coupling. Insulin acts as a true inotrope without increasing myocardial oxygen consumption or triggering arrhythmogenic catecholamine surges. Furthermore, insulin decreases systemic vascular resistance in microvascular beds, reducing left ventricular afterload.

Clinical Protocol, Dosing, and Titration

Because the inotropic effects of HIE require 15 to 45 minutes to take effect and peak at 60 to 90 minutes, HIE must be initiated early in symptomatic patients rather than held as a salvage therapy after multiple vasopressors have failed.

Step 1: IV Regular Insulin Bolus (1 unit/kg)
        + D50W (25-50 g IV) if baseline glucose <250 mg/dL
        ↓
Step 2: Continuous IV Regular Insulin Infusion (1 unit/kg/hr)
        ↓
Step 3: Titrate Insulin upward by 1-2 units/kg/hr every 15-30 min
        Target: SBP >90-100 mmHg, MAP >65 mmHg, HR >50 bpm
        (Range: 1 to 10 units/kg/hr)
        ↓
Step 4: Continuous Dextrose Infusion (D10W or D50W via Central Line)
        Titrate to maintain blood glucose 100-200 mg/dL (serial bedside glucose q15-30m)
        ↓
Step 5: Serum Potassium Surveillance: Maintain target 2.8-3.2 mEq/L
        Do NOT aggressively replete K+ unless <2.5-2.8 mEq/L (intracellular shift, not loss)

1. Initial Bolus: Administer 1 unit/kg of regular human insulin IV push. Co-administer 25 to 50 g of dextrose (50 to 100 mL of D50W) as an IV bolus unless the baseline bedside blood glucose is >250 mg/dL (as frequently seen in acute CCB toxicity).
2. Maintenance Infusion: Initiate a continuous regular insulin infusion at 1 unit/kg/hour.
3. Dose Escalation: If hemodynamics remain compromised (systolic blood pressure <90 mmHg, MAP <65 mmHg, or persistent severe bradycardia), titrate the insulin infusion upward by 1 to 2 units/kg/hour every 15 to 30 minutes. Dosing commonly ranges from 2 to 5 units/kg/hour, with severe refractory poisonings requiring titration up to 10 units/kg/hour (doses up to 15 units/kg/hour have been administered safely with poison center consultation).
4. Dextrose Titration and Euglycemia Maintenance: Initiate a concentrated dextrose infusion (typically 10% Dextrose in Water [D10W] peripherally, or 20% to 50% Dextrose in Water [D20W/D50W] via a dedicated central venous line to prevent fluid overload). Bedside capillary blood glucose must be monitored every 15 to 30 minutes during initiation and titration, transitioning to every 60 minutes once hemodynamically stable. Dextrose is titrated dynamically to maintain blood glucose between 100 and 200 mg/dL.
5. Potassium Monitoring and Avoidance of Aggressive Repletion: Insulin activates Na+/K+-ATPase pumps, driving extracellular potassium into skeletal muscle and hepatic cells. This causes an expected drop in serum potassium. However, total body potassium is NOT depleted. The clinical target serum potassium during HIE is 2.8 to 3.2 mEq/L. As long as serum potassium remains >= 2.8 mEq/L and no hypokalemic dysrhythmias (e.g., prominent U waves, ectopy) are present on telemetry, exogenous potassium supplementation should be withheld. Aggressive potassium repletion is dangerous: once the insulin infusion is tapered and systemic toxicity resolves, intracellular potassium shifts back into the extracellular space, triggering severe, potentially fatal rebound hyperkalemia. If potassium falls below 2.5 to 2.8 mEq/L, supplement cautiously with 10 to 20 mEq/hour IV.

---

Adjunctive and Second-Line Resuscitation Therapies

While HIE is the foundation of metabolic resuscitation, several adjunctive therapies are utilized concurrently or as bridging measures.

Calcium Salts

Intravenous calcium increases the extracellular-to-intracellular concentration gradient, driving calcium influx through unblocked L-type channels and non-L-type pathways. Calcium is more effective for reversing hypotension than bradycardia.

• Calcium Chloride (10% solution): Provides 27.2 mg of elemental calcium per mL (13.6 mEq/10 mL). Administer 10 to 20 mL (1 to 2 g) IV push over 2 to 5 minutes, repeated every 10 to 15 minutes for 3 to 4 doses. Must be administered through a secure central venous catheter due to the severe risk of thrombophlebitis and extravasation tissue necrosis.
• Calcium Gluconate (10% solution): Provides 9.3 mg of elemental calcium per mL (4.65 mEq/10 mL). Because it contains roughly one-third the elemental calcium of chloride, the equivalent adult dose is 30 to 60 mL (3 to 6 g) IV push. Preferred when only peripheral venous access is available.
• Clinical Role: Improves contractility transiently; clinical response is typically incomplete and plateaus quickly due to receptor saturation. Total ionized calcium should be monitored, targeting 1.5 to 2.0 times the upper limit of normal.

Glucagon

Glucagon binds to specific cell-surface G-protein-coupled glucagon receptors, stimulating adenylyl cyclase and increasing intracellular cAMP independently of beta-adrenergic receptors.

• Dosing: Administer an initial bolus of 3 to 10 mg IV push over 1 to 2 minutes (pediatric: 50 mcg/kg). A positive response (narrowing of pulse pressure, increased heart rate and blood pressure) should occur within 5 to 10 minutes. If effective, initiate a continuous maintenance infusion at 2 to 5 mg/hour (or an hourly rate matching the successful bolus dose).
• Limitations: Glucagon therapy is severely constrained by three factors: (1) rapid tachyphylaxis occurs within 2 to 4 hours due to receptor down-regulation and hepatic glycogen depletion; (2) intractable vomiting and nausea, which creates a catastrophic aspiration hazard in sedated or obtunded patients; and (3) limited hospital stock, because multi-hour infusions can exhaust supplies that are usually kept in small quantities.

Vasopressors and Inotropes

• Norepinephrine: The preferred first-line vasopressor for calcium channel blocker toxicity. Direct alpha-1-adrenergic stimulation restores systemic vascular resistance in dihydropyridine-induced or refractory non-dihydropyridine-induced distributive shock, while modest beta-1 agonism provides inotropic support.
• Epinephrine: The preferred inotrope when profound bradycardia and cardiogenic shock dominate, particularly in beta-blocker poisoning. Infusions are titrated from 2 to 20 mcg/min (0.05 to 0.5 mcg/kg/min).
• Avoid Pure Alpha Agonists: Pure alpha-1 agonists such as phenylephrine should be avoided; increasing systemic afterload against a severely failing, stunned left ventricle precipitously drops cardiac output.

Intravenous Lipid Emulsion (ILE / 20% Intralipid)

Intravenous lipid emulsion acts primarily as an intravascular "lipid sink", creating an expanded hydrophobic plasma compartment that sequesters lipophilic xenobiotics away from myocardial and vascular target receptors. Additionally, ILE provides direct myocardial fatty acid substrates and modulates cardiac calcium channels.

• Indications: Reserved for refractory hemodynamic collapse, life-threatening dysrhythmias, or cardiac arrest unresponsive to HIE, calcium, and maximal vasopressors. Most reported successes involve lipophilic agents such as verapamil, diltiazem, and propranolol; benefit is not expected for hydrophilic drugs (atenolol), and the overall evidence is limited to case reports and animal data.
• Dosing Protocol: Administer a bolus of 1.5 mL/kg of 20% lipid emulsion IV over 2 to 3 minutes, followed by a continuous infusion of 0.25 mL/kg/min. The bolus may be repeated once or twice for persistent arrest; the total dose is generally kept below about 12 mL/kg (the ASRA upper limit), most of it given in the first 30 to 60 minutes.
• Complications: Massive lipid infusion can cause acute pancreatitis, hypertriglyceridemia, acute respiratory distress syndrome (fat overload syndrome / ARDS), and severe laboratory interference (falsely invalidating clinical laboratory measurements of serum electrolytes, creatinine, glucose, liver enzymes, and blood gases).

Extracorporeal Life Support: VA-ECMO

For patients with refractory cardiogenic shock or ongoing cardiac arrest (E-CPR) failing pharmacotherapy, Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) provides definitive biventricular circulatory and respiratory support. Because cardiovascular drug toxicity is typically reversible once the offending xenobiotic is cleared and metabolized, VA-ECMO serves as an outstanding bridge to recovery, maintaining end-organ perfusion until intrinsic myocardial contractility returns.

---

Clinical Poison Center Case Scenario: The Amlodipine Vasoplegia Trap

A 58-year-old male with a history of hypertension is found obtunded by his family with an empty bottle of amlodipine 10 mg (prescribed 90 tablets, filled yesterday). Emergency Medical Services arrives and reports a blood pressure of 64/30 mmHg, a heart rate of 114 bpm (sinus tachycardia), and a capillary blood glucose of 342 mg/dL. In the emergency department, 2 liters of normal saline and a peripheral infusion of dopamine are started, but the blood pressure remains 68/32 mmHg.

Toxicological Consultation and Action Plan

1. Diagnostic Recognition: Massive amlodipine ingestion produces profound arteriolar vasodilation. Early in the course, reflex sinus tachycardia is preserved, but severe vasoplegia leads to fatal end-organ ischemia if uncorrected. The marked hyperglycemia (342 mg/dL) confirms severe L-type calcium channel inhibition on pancreatic beta cells.
2. Vasopressor Adjustment: Dopamine is discontinued because its largely indirect mechanism gives an unreliable pressor response in profound vasoplegia. Norepinephrine is initiated via central line and titrated to restore vascular tone.
3. HIE Initiation: A bolus of regular insulin 1 unit/kg IV (70 units) is administered without dextrose (since blood glucose is 342 mg/dL). A maintenance infusion of regular insulin at 1 unit/kg/hr is started. Blood glucose is checked every 15 minutes. Two hours later, as blood glucose falls to 180 mg/dL, a D10W infusion is co-administered.
4. Potassium Surveillance: Serum potassium falls from 4.2 to 3.0 mEq/L. The poison specialist specifically directs the team not to replete potassium, explaining that the ion has shifted intracellularly. Telemetry remains stable without ectopy.
5. Resolution: Over the next 12 hours, the insulin infusion is titrated up to 3 units/kg/hr, the patient's blood pressure stabilizes at 110/65 mmHg, and norepinephrine is successfully weaned off. The patient survives without neurological deficit.

Other Antihypertensives and Antiarrhythmics

The official topic list names antihypertensives as a group, not just beta-blockers and calcium channel blockers. Each subgroup behaves differently in overdose.

Triage pearl: for an unknown "blood pressure pill" ingestion in a toddler, the dangerous possibilities are a calcium channel blocker, a beta-blocker, and clonidine. All three require emergency evaluation and monitored observation, so the specialist does not need the exact drug to make the disposition.